Arpeggio Bioscience Inc., a preclinical-stage pharmaceutical company founded by University of Colorado Boulder doctoral program graduates, has raised a $17 million Series A fundraising round that will ...

How can drug developers design therapies around cellular networks rather than a single target? That is the question Arpeggio Biosciences is seeking to answer — and with a new influx of funds. The ...

New capital will support ongoing development of their drug pipeline targeting transcriptional mechanisms in disease Arpeggio’s technology isolates a drug’s effect on entire transcriptomes and has ...